Vilazodone

Vilazodone (EMD 68843; SB 659746A; 5-{4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide hydrochloride) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.

Crystal structure of vilazodone hydro-chloride methanol monosolvate.[Pubmed:27980830]

Acta Crystallogr E Crystallogr Commun. 2016 Nov 10;72(Pt 12):1783-1785.

In the title compound, C26H28N5O2(+).Cl(-).CH3OH {systematic name: 4-(2-carbamoyl-1-benzo-furan-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)but-yl]piperazin-1 -ium chloride methanol monosolvate}, the protonated piperazine ring adopts a chair conformation. The indole ring plane is nearly perpendicular to the benzo-furan ring system, with a dihedral angle of 85.77 (2) degrees . In the crystal, the organic cations, Cl(-) anions and methanol solvent mol-ecules are linked by classical N-Hcdots, three dots, centeredO and N-Hcdots, three dots, centeredCl hydrogen bonds, and weak C-Hcdots, three dots, centeredO and C-Hcdots, three dots, centeredpi inter-actions into a three-dimensional supra-molecular architecture.

Serotonin Syndrome in a Pediatric Patient After Vilazodone Ingestion.[Pubmed:28350718]

Pediatr Emerg Care. 2018 Dec;34(12):e226-e228.

Serotonin syndrome (SS) is a serious toxicity that manifests with symptoms such as tremor, hyperthermia, agitation, and altered mental status that may lead to seizures, coma, or death. Selective serotonin reuptake inhibitors may precipitate SS, particularly in combination with other drugs that possess serotonergic activity. We present a case of SS in a 14-month-old after an ingestion of the selective serotonin reuptake inhibitor Vilazodone.

Double-blind switch study of vilazodone in the treatment of major depressive disorder.[Pubmed:28177953]

Int Clin Psychopharmacol. 2017 May;32(3):121-126.

Approximately 40% of patients treated for depression do not respond to a trial of an antidepressant. The aim of the proposed study was to evaluate the efficacy and safety of switching to Vilazodone in patients with major depressive disorder who are unresponsive or only partially responsive to a trial of citalopram. Seventy-nine adults with major depressive disorder were enrolled in an open-label study of citalopram (20 mg/day) for 6 weeks. Those still symptomatic after 6-weeks of citalopram were randomly assigned to either a higher dose of citalopram (40 mg/day) or to Vilazodone in a double-blind trial for 6 weeks. Of those who received citalopram 20 mg/day for 6 weeks, 20.3% were 'responders' (defined as >/=50% reduction on the Montgomery-Asberg Depression Rating Scale). Of the 42 who did not respond, 23 were assigned to citalopram 40 mg/day and 19 were randomized to 40 mg/day of Vilazodone. Both groups showed decreases in all outcome measures, but there were no significant differences between groups. Initial nonresponders to a low dose of citalopram seem equally likely to respond to a higher dose of citalopram or to Vilazodone. Whether to increase an selective serotonin reuptake inhibitor or switch to a different antidepressant may be best determined on the basis of their adverse event profile.

Vilazodone (EMD 68843; SB 659746A) is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist currently under clinical evaluation for the treatment of major depression.

Vilazodone,163521-12-8,Natural Products,5-HT Receptor, buy Vilazodone , Vilazodone supplier , purchase Vilazodone , Vilazodone cost , Vilazodone manufacturer , order Vilazodone , high purity Vilazodone